Athersys and Turn Therapeutics Battle for Biotech Supremacy

Two small-cap manufacturing companies compete for investors' attention.

Apr. 3, 2026 at 8:24pm

Got story updates? Submit your updates here. ›

A minimalist, photorealistic studio still life featuring a set of polished, geometric objects arranged elegantly on a clean, monochromatic background, conceptually representing the abstract concepts of corporate strategy, finance, and market competition within the biotech industry.Premium materials and clean geometric shapes symbolize the high-stakes competition between biotech firms vying for investor capital and market share.Westlake Village Today

Turn Therapeutics (NASDAQ:TTRX) and Athersys (NASDAQ:ATHX) are both small-cap biotech companies, but which one is the better investment? The two companies are being compared based on factors like profitability, institutional ownership, earnings, and analyst recommendations to determine which stock comes out on top.

Why it matters

The biotech industry is highly competitive, with smaller companies constantly vying for investor capital and market share. Understanding the relative strengths and weaknesses of Turn Therapeutics and Athersys can help investors make informed decisions about where to allocate their resources.

The details

Turn Therapeutics and Athersys both operate in the pharmaceutical and medical device development space, but they have different approaches and focus areas. Turn Therapeutics' proprietary PermaFusion technology aims to enhance drug performance, while Athersys is focused on regenerative medicine and its lead product MultiStem. The companies have different financial profiles, with Turn Therapeutics reporting higher earnings but lower revenue compared to Athersys.

  • Turn Therapeutics was initially formed as Global Health Solutions, LLC in 2015 and converted to a Delaware corporation in 2018.
  • Athersys was founded in 1995 and is headquartered in Cleveland, Ohio.

The players

Turn Therapeutics

A pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance.

Athersys, Inc.

A biotechnology company that focuses on research and development activities in the field of regenerative medicine, with a lead platform product called MultiStem cell therapy.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching for updates on the progress of Turn Therapeutics' and Athersys' respective drug development programs, as well as any potential collaborations or partnerships that could drive future growth.

The takeaway

The battle between Turn Therapeutics and Athersys highlights the competitive nature of the biotech industry, where smaller companies must constantly innovate and differentiate themselves to attract investor interest and capital. The outcome of this rivalry could have significant implications for the future of both companies and the broader biotech landscape.